[Cocarnit in complex therapy of diabetic peripheral polyneuropathy].

OBJECTIVE

Study of the effectiveness of Cocarnit drug in diabetic peripheral polyneuropathy (DPPN) combination therapy.

MATERIAL AND

METHODS

The study involved 40 patients with DPPN aged 38 to 74 years (mean age 62.33±1.27 years), with type 2 diabetes mellitus 2-36 years duration (mean 12.38±1.25 years); 4 months to 28 years (mean 6.27±1.06 years) had passed since the first symptoms of polyneuropathy. They received Cocarnit 2 ml per day for 18 days and gabapentin with individual dose selection.

RESULTS

The treatment shows significant decrease of pain intensity in patients with positive dynamics from «severe» at the beginning of the study to «weak» by the end of the study. Significant positive dynamics of the severity of neuropathy symptoms during the combined therapy were shown by DN4 questionnaire and the NSS scale, assessment of complaints and physical examination results using the MNSI diagnostic questionnaire, and the general clinical impression on the CGI-C scale. A positive tendency in the s-ENMG results was revealed with more significant improvement changes in the axoplasmic amperage along the peroneal nerve, superficial peroneal nerve and the feet VCSP. The results of the quality of life assessment objectively confirm the improvement in the patients' condition as a result of the therapy. The doses of gabapentin during Cocarnit treatment were low and did not reach the usual therapeutic doses, against the background of a statistically significant decrease in pain syndrome.

CONCLUSION

Cocarnit is an effective drug for patients with DPPN treatment. The combined use of Cocarnit with gabapentin allows to reduce the dose of gabapentin and the risk of its side effects helping to restore peripheral nerves in DPPN.